Market Overview

Opko Health Inks Pfizer License Pact


Opko Health Inc. (NYSE: OPK) gained more than 9 percent Monday after the developmental drug company licensed its growth hormone treatment to Pfizer Inc. (NYSE: PFE).

Opko will receive a payment of $295 million up front and is eligible to receive up to an additional $275 million if the unapproved drug reaches "certain regulatory milestones," GEN News reported.

Related Link: Opko Health Chairman Frost Tells Benzinga No Secondary Offering Planned In Near Future

Opko, which posted 2013 revenue of $93.7 million, is also eligible to receive initial royalty payments associated with the commercialization.

The deal is subject to anti-trust review and is expected to close in the first quarter.

Drug Profile

The drug, called hGH-CTP, has orphan drug status in the U.S. and Europe for both adults and children.

Currently in a Phase III trial in adults and a Phase II trial in children, the drug aims to treat growth hormone deficiency as well as growth failure in children.

Opko will fund further development costs while Pfizer will pay for commercialization, manufacturing and post-marketing studies.

Opko changed hands recently at $8.93, up 9.05 percent.


Related Articles (OPK)

View Comments and Join the Discussion!

Posted-In: hGH-CTPNews Contracts FDA